Microparticles in acute coronary syndrome

Mavroudis, C; Eleftheriou, Despina; Hong, Ying; Majumder, Bikash; Koganti, Sudheer; Sapsford, RJ; North, Janet; Lowdell, Mark W.; Klein, Nigel; Brogan, Paul A.; Rakhit, Roby

doi:10.1016/j.thromres.2017.06.003

Cited by 19 publications

(9 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, STEMI patients had elevated absolute levels of total Annexin V + EV compared to VA-ECMO patients. This is in line with previous reports of elevated EV concentrations in STEMI patients compared to other patients with vascular inflammation, e.g., NSTEMI patients, patients recovering from STEMI and patients with stable angina (22,(39)(40)(41)(42). Elevated EV levels most likely reflect the release of MV during the thrombotic process, from activated cells and from the ischemic myocardium after reperfusion (17,43).…”

Section: Discussionsupporting

confidence: 91%

“…Levels of leukocyte (CD45 + ) EV did not differ significantly in VA-ECMO and STEMI patients. This is most likely due to the fact that increased levels of leukocyte EV have been reported in both ECMO (10,38) and STEMI patients (42). Interestingly, the level of leukocyte EV was increased in nonsurvivors of VA-ECMO therapy indicating an association with outcome.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Data_Sheet_1.pdf

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 92%

Data_Sheet_1.pdf

View full text Add to dashboard Cite

“…Emerging evidence indicates that EVs released from activated cells contain procoagulant and proinflammatory molecules that may contribute to thrombus formation and endothelial dysfunction . Several clinical studies have shown a correlation between circulating EVs levels and clinical outcomes, markers of myocardial damage, inflammation, and evidences of microvascular dysfunction . Likewise, circulating EVs are shown to be increased in patients with ACS compared with healthy and stable coronary artery disease (SCAD) individuals pointing toward the importance of EVs as novel prognostic biomarkers to predict the outcome of ACS patients .…”

Section: Evs Proteomics In Cardiovascular Diseasementioning

confidence: 99%

Application of Extracellular Vesicles Proteomics to Cardiovascular Disease: Guidelines, Data Analysis, and Future Perspectives

et al. 2019

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are a heterogeneous population of vesicles composed of a lipid bilayer that carry a large repertoire of molecules including proteins, lipids, and nucleic acids. In this review, some guidelines for plasma‐derived EVs isolation, characterization, and proteomic analysis, and the application of the above to cardiovascular disease (CVD) studies are provided. For EVs analysis, blood samples should be collected using a 21‐gauge needle, preferably in citrate tubes, and plasma stored for up to 1 year at −80°, using a single freeze–thaw cycle. For proteomic applications, differential centrifugation (including ultracentrifugation steps) is a good option for EVs isolation. EVs characterization is done by transmission electron microscopy, particle enumeration techniques (nanoparticle‐tracking analysis, dynamic light scattering), and flow cytometry. Regarding the proteomics strategy, a label‐free and gel‐free quantitative method is a good choice due to its accuracy and because it minimizes the amount of sample required for clinical applications. Besides the above, main EVs proteomic findings in cardiovascular‐related diseases are presented and analyzed in this review, paying especial attention to overlapping results between studies. The latter might offer new insights into the clinical relevance and potential of novel EVs biomarkers identified to date in the context of CVD.

show abstract

“…These are prothrombotic and proinflammatory 10,11 . The levels of PS-exposing EVs are increased in many cardiovascular and metabolic disorders [12][13][14][15][16][17] , and platelets are the major source of circulating PS-exposing EVs 11,18 . The pathological role of PSexposing EVs, and their elevation in a range of diseases, makes them an attractive therapeutic target.…”

Section: Introductionmentioning

confidence: 99%

2-Aminoethoxydiphenylborate (2-APB) inhibits release of phosphatidylserine-exposing extracellular vesicles from platelets

2020

View full text Add to dashboard Cite

Activated, procoagulant platelets shed phosphatidylserine (PS)-exposing extracellular vesicles (EVs) from their surface in a Ca 2+-and calpain-dependent manner. These PS-exposing EVs are prothrombotic and proinflammatory and are found at elevated levels in many cardiovascular and metabolic diseases. How PS-exposing EVs are shed is not fully understood. A clearer understanding of this process may aid the development of drugs to selectively block their release. In this study we report that 2-aminoethoxydiphenylborate (2-APB) significantly inhibits the release of PSexposing EVs from platelets stimulated with the Ca 2+ ionophore, A23187, or the pore-forming toxin, streptolysin-O. Two analogues of 2-APB, diphenylboronic anhydride (DPBA) and 3-(diphenylphosphino)-1-propylamine (DP3A), inhibited PS-exposing EV release with similar potency. Although 2-APB and DPBA weakly inhibited platelet PS exposure and calpain activity, this was not seen with DP3A despite inhibiting PS-exposing EV release. These data suggest that there is a further target of 2-APB, independent of cytosolic Ca 2+ signalling, PS exposure and calpain activity, that is required for PS-exposing EV release. DP3A is likely to inhibit the same target, without these other effects. Identifying the target of 2-APB, DPBA and DP3A may provide a new way to inhibit PS-exposing EV release from activated platelets and inhibit their contribution to thrombosis and inflammation.

show abstract

Microparticles in acute coronary syndrome

Abstract: Background

Cited by 19 publications

References 57 publications

Data_Sheet_1.pdf

Data_Sheet_1.pdf

Application of Extracellular Vesicles Proteomics to Cardiovascular Disease: Guidelines, Data Analysis, and Future Perspectives

2-Aminoethoxydiphenylborate (2-APB) inhibits release of phosphatidylserine-exposing extracellular vesicles from platelets

Contact Info

Product

Resources

About